FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Vaxart, Inc. Skyrockets Following New Details of its COVID-19 Vaccine ”
Vaxart, Inc. (NASDAQ: VXRT) is up over 15% above its previous close by midday trading after announcing additional results from its COVID-19 Hamster Challenge Study.
The Company reported a significant reduction in lung viral loads for hamsters that received two doses of its oral vaccines without the systemic weight loss that was seen in unvaccinated animals, raising prospects of the vaccine’s efficacy.
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication.
For more information, please visit: Vaxart, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.